Steve Lee, MD
Interventional Pain Medicine · Slidell, LANPI 1699971465
Payments from drug & device makers
Across 899 payments — averaging $67.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Interventional Pain Technologies Inc.$15K
- Saluda Medical Americas, Inc.$6K
- Nevro Corp.$6K
- Boston Scientific$5K
- Spinal Simplicity, LLC$4K
- Surgentec$3K
- plus $22K from 54 others
What the payments were for
- Consulting fees$14,20025%
- Speaking & faculty fees$1,0002%
- Travel & lodging$8,49215%
- Food & beverage$21,23938%
- Education$11,57220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$4,502
- LIBERTY SI$3,286
- TiLink$3,229
- ION$3,075
- Senza Spinal Cord Stimulation System$1,966
- Evoke SCS$1,472
- SACROILIAC JOINT FUSION SYSTEM$1,083
- INTELLIS ADAPTIVESTIM$1,018
- Intracept$750
- mild Device Kit$745
- Omnia$730
- Probuphine$713
- Senza$499
- Nalu Neurostimulation System$479
- Iovera$346
- PROCLAIM$280
- HA MINUTEMAN G3-R$205
- ETERNA$167
- ION Facet Screw System$154
- SiFix$130
How this compares
$60,903 in reported general payments places this provider in the 90th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 203 | $175,123 |
| Xtampza ErOxycodone Myristate | 288 | $133,384 |
| Levorphanol Tartrate | 37 | $97,364 |
| Buprenorphine | 173 | $56,813 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 886 | $29,198 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 155 | $21,269 |
| OxycontinOxycodone Hcl | 40 | $20,289 |
| Nucynta ErTapentadol Hcl | 14 | $15,433 |
| HorizantGabapentin Enacarbil | 21 | $14,153 |
| GraliseGabapentin | 16 | $13,161 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 23 | $12,815 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 908 | $12,499 |
| NucyntaTapentadol Hcl | 15 | $11,425 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $10,253 |
| Morphine Sulfate ErMorphine Sulfate | 284 | $6,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta | $1,353 | $335,364520 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $345 | $97,36437 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $339 | $14,15321 claims |
| Almatica Pharma LLCGralise | $155 | $13,16116 claims |
| Orexo US, Inc.Zubsolv | $49 | $12,81523 claims |
| Indivior Inc.Suboxone | $137 | $10,25320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Slidell
- Tod AustSlidell$11K
- Maged GuirguisNew Orleans$1.7M
- Suneil JollyKenner$465K
- Adam CarinciBaton Rouge$92K
- John CefaluShreveport$71K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.